volume retention on MRI volumetric analysis (38%, 41% respectively) on POD84. The 100% composite only group had the poorest volume retention (14%) on POD 84. On IHC, groups containing the nanofiber-hydrogel composite demonstrated superior rates of angiogenesis and blood vessel ingrowth into the graft as compared to lipoaspirate and lipoaspirate/hydrogel only groups. Furthermore, adipocyte morphology was better preserved in groups containing the nanofiber-hydrogel composite.
The purpose of the present clinical study was to investigate the effects of ADSC therapeutic introduction into the facial skin of patients with overt photo-ageing, 1 with special attention to morphological modifications of the dermal extracellular matrix. The chosen strategy was to compare histology and histopathology of the treated and non-treated skin, harvested from patients that were going to be submitted to facial rejuvenation through surgical face-lifting. 2, 3 This prospective, clinical, randomized study involved twenty healthy subjects, 4 males and 16 females, candidates for facial rejuvenation surgery (face lifting). They aged from 45 to 65 years. The study was done between September 2012 and June 2014. They were inhabitants of the northeast region of Brazil, where an extensive exposure to sun is expected, and they presented class IV (n= 9), and V (n= 11) Fitzpatrick' s classification of the skin [21] . Patients were treated according to the ethical principles of the Declaration of Helsinki 2000, and the present study was approved by the Brazilian Medical Investigation Ethical Board (Protocol no. 28063) and the Brazilian Clinical Trials Registry (RBR-2nn9y2).
Mesenchymal stem cells were obtained from lipoaspirates, expanded in vitro 4 , and introduced into the facial skin of patients to be submitted after four months to a face-lifting surgery. The retrieved face skin was analyzed by immunocytochemistry for identification and quantification of the elastic matrix components, cathepsin-K, metalloelastase M-12, and macrophage M2 markers CD68, CD206 and heme-oxygenase-1.
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RESULTS: A full de novo formation of oxytalan and elaunin fibers was observed in the sub-epidermal region, with full reconstitution of the papillary dermal-epidermal junction. Elastotic deposits in the deep dermis were substituted by a normal elastin fiber network. The coordinated removal of the pathologic deposits and their substitution by the normal ones was concomitant with activation of cathepsin-K and MPP12, and expansion of the M2 macrophage infiltration.
CONCLUSION:
Adipose Derived Stem Cell therapy of solar elastosis fully regenerates skin extracellular matrix, with restoration of a normal elastin network in the subepidermal zone and substitution of elastotic deposits by normal elastin fibers in the deep dermis. This may be a promising cell-therapy for sun-aged skin regeneration. 
METHODS:
In vitro and animal studies (using immunocompromised and wild type rodent models) were conducted to determine cellular ingrowth, vasculogenesis, adipogenesis and volume retention. A 16-week prospective clinical study evaluated subcutaneous AAM injection (2.5-5cc) of the dorsal wrist of 15 subjects to determine patient safety, graft retention, and histological characteristics. A clinical trial was then conducted by injecting 20cc of AAM into 6 individual abdominal subcutaneous sites of 10 subjects. Subjects were randomized to panniculectomy either 3 or 6 months after injection, and biopsies were taken at 1 and 2 months. Safety of AAM and histology of specimens obtained at biopsy and surgery were determined.
RESULTS:
In vitro seeding of ASCs on AAM, showed attachment and proliferation of ASCs for 3 days, followed by production of new matrix within 7 days and changes to adipocyte morphology. AAM injected on the dorsum of immunocompromised nude mice supported adipogenesis at 6 weeks, with progressive increase in adipocyte frequency at 12-24 weeks and graft retention of 44 ± 16% at 24 weeks. AAM injected in the dorsal flanks of immunocompetent Fisher rats showed higher graft retention (89 ± 16%) up to 3 weeks, and induction of anti-inflammatory M2a macrophages as early as 72 hours compared to controls and alternative ECM derived products. 
